Order Article Reprints

Anshabo AT, Bantie L, Diab S, Lenjisa J, Kebede A, Long Y, Heinemann G, Karanjia J, Noll B, Basnet SKC, et al. An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers. 2022; 14(5):1113. https://doi.org/10.3390/cancers14051113

Anshabo, Abel Tesfaye, Laychiluh Bantie, Sarah Diab, Jimma Lenjisa, Alemwork Kebede, Yi Long, Gary Heinemann, Jasmine Karanjia, Benjamin Noll, Sunita K. C. Basnet, and et al. 2022. "An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia" Cancers 14, no. 5: 1113. https://doi.org/10.3390/cancers14051113

Anshabo, A. T., Bantie, L., Diab, S., Lenjisa, J., Kebede, A., Long, Y., Heinemann, G., Karanjia, J., Noll, B., Basnet, S. K. C., Li, M., Milne, R., Albrecht, H., & Wang, S. (2022). An Orally Bioavailable and Highly Efficacious Inhibitor of CDK9/FLT3 for the Treatment of Acute Myeloid Leukemia. Cancers, 14(5), 1113. https://doi.org/10.3390/cancers14051113